Mineralys Therapeutics, Inc. MLYS Deferred offering costs
Deferred offering costs at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredOfferingCosts.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
The Company capitalizes certain legal, professional, accounting, and other third-party fees that are directly associated with in-process equity issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be abandoned, the deferred offering costs are expensed immediately as a charge to operating expenses in the condensed statements of operations. Deferred offering costs as of each of March 31, 2026 and December 31, 2025 were $0.2 million. Such costs are classified in other assets on the condensed balance sheets.
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s deferred offering costs?
- Mineralys Therapeutics, Inc. (MLYS) reported deferred offering costs of $200K in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s deferred offering costs changed year-over-year?
- Mineralys Therapeutics, Inc.'s deferred offering costs decreased by 33.3% year-over-year, from $300K to $200K.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s deferred offering costs?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s deferred offering costs has grown at a -50.0% compound annual growth rate (CAGR), from $1.6M to $200K.
- What does deferred offering costs mean?
- These are capitalized costs directly attributable to a planned or ongoing equity or debt offering that have not yet been recognized in the income statement. Once the offering is completed, these costs are typically reclassified as a reduction of the proceeds from the offering.
Ask your AI about Mineralys Therapeutics, Inc.'s deferred offering costs.
Connect your AI assistant and compare it to peers, right in your chat.
